Lipella Pharmaceuticals Re-signs Manufacturing Collaboration Agreement with Cook MyoSite to Support LP-310 Clinical Development
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 04 2025
0mins
Should l Buy ?
Source: Newsfilter
Collaboration Renewal: Lipella Pharmaceuticals has renewed its manufacturing collaboration agreement with Cook MyoSite to support the Chemistry, Manufacturing and Control (CMC) documentation for its clinical products LP-10 and LP-310.
Company Focus: Lipella is a clinical-stage biotechnology company aiming to develop therapies for diseases with significant unmet needs by reformulating existing generic drugs, having completed its IPO in 2022.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
